TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06560008

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EnXtra® (300 mg) + Placebo (300 mg)
Description: Two capsules to be taken after breakfast orally once a day (4 single doses in Acute stage and for 28 days in sub-acute stage)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine (200 mg) + Placebo (300 mg)
Description: Two capsules to be taken after breakfast orally once a day (4 single doses in Acute stage and for 28 days in sub-acute stage)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EnXtra® (300 mg) + Caffeine (200 mg)
Description: Two capsules to be taken after breakfast orally once a day (4 single doses in Acute stage and for 28 days in sub-acute stage)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (MCC 300 mg) + Placebo (300 mg)
Description: Two capsules to be taken after breakfast orally once a day (4 single doses in Acute stage and for 28 days in sub-acute stage)
Study: NCT04909190

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Increased saline flush volume
Description: Additional flushing of the stentgraft delivery system.
Study: NCT06562699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot Matcha brew
Description: * Hot matcha brew will be prepared in usucha (thin consistency) version-2 grams of matcha powder (Dr.Baby) mixed with 30 mL of hot water (75 ̊C). The first step will be to massage the matcha powder with a small amount of water until a smooth paste forms, then additional 50 mL of hot water will be added to dilute down the concentration. The matcha will then be vigorously shaken in a lidded jar.~* After 5 minutes of the acidic attack, participants will be instructed to swish 25 mL of matcha tea 34 times then swallow, and saliva samples will be collected (T2).~* Then saliva will be collected after 10 (T3), 20 (T4), 30 (T5), and 40 (T6) minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Water (elano) at 13 ̊C swished 34 times then swallowed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold matcha brew
Description: 25 mL of cold matcha brew prepared in usucha (thin consistency) version-2 grams of matcha powder (Dr.Baby) mixed with 80 mL of cold water (13 ̊C) swished 34 times then swallowed.
Study: NCT04972864

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training group
Description: A regular advanced exercise program was given and followed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control training group
Description: Basic exercises was given at the beginning and did the same exercises
Study: NCT05815745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker - Physiological pacing
Description: The approach for physiological pacing will be either His bundle pacing or left bundle pacing at the operator's discretion. If both of these are not achieved biventricular pacing will be performed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker - Right Ventricular pacing
Description: Right ventricular pacing (apical or septal lead locations as per the implanting physicians' normal practice).
Study: NCT06558162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfetalness
Description: They will be instructed to lie on their left side and focus on the fetal movements for 15 minutes every day while the foetus is awake. They will also be instructed to monitor the character, strength and frequency of fetal movements (not to count them) and to seek medical advice if they feel any change in this pattern.~After two weeks, the pregnant women will be invited back to the organisation for a follow-up interview to check whether they have performed the practice and recorded correctly. An interview will be conducted again after four weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sadovsky
Description: They will be asked to continue this procedure every morning, noon or evening for one month (depending on the movements of the pregnant woman and her baby, the time will be left to the pregnant woman, but it should be at the same time every day). Since the aim of the study is to increase maternal awareness rather than to determine fetal well-being, mothers will be asked to count at least 10 movements based on the count to ten and Sadovsky method, and will be asked to record the start and completion time of the movements each time. A follow-up will be made after two weeks and a final follow-up will be made after one month
Study: NCT06510998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: isometric wall exercise
Description: Each exercise session will contain 4 sets of 2-minute wall squat isometric holds with 2 minutes of rest between each set (approximately 14 minutes per session in total), and a total of 3 sessions will be arranged every week (with ideally 48 h between exercises)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: passive stretching
Description: A frequency-matched (3x/week) and time-matched (\~14 minutes each session) passive static stretching exercise will be used
Study: NCT04919629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Description: Given IV and SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Description: Given IV and SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Description: Given IV and SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Description: Given IV and SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT05690243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group psychotherapy delivered via video telehealth
Description: Small group psychotherapy using psychoeducation and skills training aimed at addressing modifiable factors in MCI.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group psychotherapy delivered via video telehealth
Description: Small group psychotherapy using psychoeducation and skills training aimed at addressing modifiable factors in MCI.
Study: NCT06442631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyStroke
Description: MyStroke is a video-based educational platform that curates brief educational videos to inform patients and caregivers about key aspects of their stroke. Upon registering a user, information regarding the patient's stroke etiology, relevant stroke risk factors, and stroke prevention medications are used to populate educational content that is relevant to the individual. Users receive automated nudges to revisit MyStroke after hospital discharge on day 1, 3, 5, 7, and weekly thereafter.
Study: NCT06345196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interview
Description: Motivational interviewing will be conducted in four sessions and the session duration will be maximum 40 minutes. The session will be conducted individually and online once a week. For the individual interview, the appropriate day and time will be determined with the individuals with diabetes and the researcher before the first session and the sessions will continue on the same day and time every week. The researcher will remind the participant about the time of the session by calling the participant by phone one day before each session. Motivational interview sessions will be held online on the Whatsapp platform.
Study: NCT06506305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB1001
Description: Intravitreal (IVT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB1001
Description: Intravitreal (IVT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB1001
Description: Intravitreal (IVT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB1001
Description: Intravitreal (IVT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB1001
Description: Intravitreal (IVT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB1001
Description: Intravitreal (IVT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB1001
Description: Intravitreal (IVT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB1001
Description: Intravitreal (IVT) injection
Study: NCT04730414

Intervention type: DRUG
Intervention: Full-spectrum hemp (0.018% THC)
Description: Topical Application
Study: NCT05224011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boppli Infant Blood Pressure Monitor
Description: The intervention is a medical device for the non-invasive measurement of blood pressure in infants
Study: NCT04919629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT05363904

Intervention type: OTHER
Intervention: Observation
Description: Questionnaires, Clinical Scores, Biomaterial Sampling

Intervention type: OTHER
Intervention: Observation
Description: Questionnaires, Clinical Scores, Biomaterial Sampling

Intervention type: OTHER
Intervention: Observation
Description: Questionnaires, Clinical Scores, Biomaterial Sampling

Intervention type: OTHER
Intervention: Observation
Description: Questionnaires, Clinical Scores, Biomaterial Sampling
Study: NCT04919629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05363904

Intervention type: OTHER
Intervention: Observation
Description: Questionnaires, Clinical Scores, Biomaterial Sampling

Intervention type: OTHER
Intervention: Observation
Description: Questionnaires, Clinical Scores, Biomaterial Sampling
Study: NCT05285969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview
Description: The new CR program with MI will be structured in 4 sessions and an optional fifth during the six months after discharge. The methodology of the MI sessions will follow the four phases logical sequence of MI proposed by Rollnick and Millner. 1) engage in a collaborative relationship, 2) focus on a particular change, 3) evoke intrinsic motivations for change, and 4) plan an immediate step for change

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Standard care group
Description: All patients in the control group will receive a kit with informative material with the actions and procedures to follow (diet, physical activity, smoking cessation, and other recommendations about secondary prevention).
Study: NCT04919629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05034224

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Swan-Ganz catheter placed in the coronary sinus - deflated
Description: A normal Swan-Ganz catheter will be advanced in the coronary sinus. The Balloon will be kept deflated during sham intervention. The index of microvascular resistances will be measured using the Abbott Pressure Wire X as per instructions for use durng both interventions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Swan-Ganz catheter placed in the coronary sinus - inflated
Description: A normal Swan-Ganz catheter will be advanced in the coronary sinus. The Balloon will be inflated to obtain coronary sinus occlusion during the active intervention. The index of microvascular resistances will be measured using the Abbott Pressure Wire X as per instructions for use durng both interventions.
Study: NCT04392440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIAL-SDM
Description: Communication intervention for nephrologists and coaching intervention for patients.

Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: regular nephrology care
Study: NCT04299282

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CanGaroo
Description: CIED ECM envelope
Study: NCT06229184

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fecal Calprotectin Test
Description: Fecal samples are taken fom obese and healthy adolescents for study

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fecal Calprotectin Test
Description: Fecal samples are taken fom obese and healthy adolescents for study

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fecal Calprotectin Test
Description: Fecal samples are taken fom obese and healthy adolescents for study
Study: NCT05865327

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoneurolysis
Description: Cryoneurolysis will be performed on the intercostal nerve associated with each fractured rib using a handheld cryoneurolysis machine (Iovera). Cryoneurolysis will consist of two 103 second cycles (includes cooling, ice ball formation and warming time) per rib fracture level. Ultrasound guidance will be used to identify appropriate rib fracture levels and to target the device tip in real time. All participants will also receive standard multimodal analgesia and ESP catheter infusion.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Cryoneurolysis
Description: Participants in the control group will receive sham CN (i.e., application of device without skin puncture or activation of unit) to maintain participant blinding. All participants will also receive standard multimodal analgesia and ESP catheter infusion.
Study: NCT05305430

Intervention type: DEVICE
Intervention: Synergy Cervical Disc System
Description: motion preservation disc

Intervention type: DEVICE
Intervention: Synergy Cervical Disc System
Description: motion preservation disc
Study: NCT05852288

Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammatory markers
Description: Participants in this cohort will undergo a comprehensive clinical and biochemical evaluation to assess the role of inflammation in CTS. The evaluation will include assessments of inflammatory markers, such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), as well as clinical measures of CTS severity.
Study: NCT04681300

Intervention type: OTHER
Intervention: Skin biopsy
Description: a skin sample will be taken using a 4 mm punch biopsy in lesional skin

Intervention type: OTHER
Intervention: Plastic surgery remnants
Description: healthy skin from plastic surgery interventions
Study: NCT04656665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: For patients at high risk of pre-eclampsia, start taking aspirin from 12-20 weeks of pregnancy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: For patients at high risk of pre-eclampsia, start taking aspirin from 12-20 weeks of pregnancy
Study: NCT05664854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nerve cuff electrodes for spatially selective vagus nerve stimulation and electrical impedance tomography
Description: Vagus nerve electrode cuffs will be placed on the exposed human vagus nerve during routine vagal nerve stimulator implantation surgery. These cuffs will then be used for spatially selective vagus nerve stimulation, with physiological readout, and electrical impedance tomography for the functional imaging of organ-specific regions in the nerve at cervical level.
Study: NCT06046157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast milk-scented PIOMI
Description: During PIOMI, the scent of breast milk will be provided through cotton soaked in breast milk placed 1.5 cm away from the babies.~PIOMI: Oral motor intervention for premature infants is a standardized oral motor therapy for preterm infants that has been shown to have strong intervention fidelity and has been tested internationally.~It is a 5-minute, 8-step focused therapy designed to help the premature baby respond functionally to lip, chin and lip movements and pressure, applied for 7 consecutive days using all aseptic precautions with gloved fingers.~Intervention provides assisted movement to activate muscle contraction and movement against resistance to build strength.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast milk-tasting PIOMI
Description: The finger used during PIOMI application will be performed by dipping it into breast milk. This will ensure that babies taste breast milk.~PIOMI: Oral motor intervention for premature infants is a standardized oral motor therapy for preterm infants that has been shown to have strong intervention fidelity and has been tested internationally.~It is a 5-minute, 8-step focused therapy designed to help the premature baby respond functionally to lip, chin and lip movements and pressure, applied for 7 consecutive days using all aseptic precautions with gloved fingers.~Intervention provides assisted movement to activate muscle contraction and movement against resistance to build strength.
Study: NCT04168710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESP block with bupivacaine
Description: Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of 0.25% bupivacaine in the plane between the transverse process of the spine and the erector spinae muscle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline control/sham injection
Description: Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of normal saline in the plane between the transverse process of the spine and the erector spinae muscle.
Study: NCT05468125

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: guidance
Description: either follow the care bundle or the best evidence practice

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: guidance
Description: either follow the care bundle or the best evidence practice
Study: NCT05693467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone palmitate emulsion(DXP) plus ropivacaine
Description: The local infiltration solution in the dexamethasone palmitate emulsion(DXP) plus ropivacaine group will consist of ropivacaine and dexamethasone palmitate emulsion(DXP). For local infiltration, a total of 30mL solution will be prepared for each group, which will include 2mL of DXP(4mg per 1mL) added to 20.5 mL of saline and 7.5mL of 1% ropivacaine added to 15mL of saline for Group A . The surgeon will perform incision infiltration before the skin incision. A total of 10 mL of solution will be injected into each level. The study solution will be injected into the entire thickness of the planned incision site. The epidural space and intrathecal space will not be infiltrated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine alone
Description: The local infiltration solution in the ropivacaine alone group will consist of ropivacaine alone. For local infiltration, a total of 30mL solution will be prepared for each group, which will include 7.5mL of ropivacaine added to 22.5mL of saline for Group B . The surgeon will perform incision infiltration before the skin incision. A total of 10 mL of solution will be injected into each level. The study solution will be injected into the entire thickness of the planned incision site. The epidural space and intrathecal space will not be infiltrated.
Study: NCT05992025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Intervention with physical activity more than 150 minutes of medium to high intensity per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene
Description: Intervention with sleep hygiene to optimize sleep duration and quality.
Study: NCT04817774

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TX200-TR101
Description: TX200-TR101 is an autologous gene therapy medicinal product composed of Treg cells (CD4+/CD45RA+/CD25+/CD127low/neg) that have been ex vivo expanded and transduced with a lentiviral vector encoding for a CAR to recognize HLA-A\*02. Treatment will be given via an IV infusion at a pre-defined timepoint several weeks after transplant. Four, single ascending dose cohorts of TX200-TR101 are planned and an additional expansion cohort.
Study: NCT06359847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-1898 tablets
Description: Tablets: 5 mg and 40 mg
Study: NCT06196580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide; midazolam; SHR4640
Description: repaglinide; midazolam; SHR4640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide; midazolam; SHR4640; SHR4640 placebo
Description: repaglinide; midazolam; SHR4640; SHR4640 placebo
Study: NCT04910425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 DCFPyL
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobenate Dimeglumine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiparametric Magnetic Resonance Imaging
Description: Undergo mpMRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transrectal Ultrasonography Guided Biopsy
Description: Undergo TRUS-guided biopsy